PHYH — phytanoyl-CoA hydroxylase

The PHYH gene provides the instructions for making an important enzyme called phytanoyl-CoA hydroxylase. This enzyme acts like a specialized recycling worker inside our cells, specifically in compartments called peroxisomes. Its main job is to break down a specific type of fat called phytanic acid. Phytanic acid is not made by our bodies; we only get it from the foods we eat, particularly dairy products, beef, lamb, and certain types of fish. When the PHYH gene has a mutation, the enzyme it produces doesn't work properly or is missing entirely. As a result, the body cannot break down phytanic acid, causing it to build up to toxic levels in the blood and tissues. This buildup is particularly harmful to the nervous system and the eyes, leading to a condition known as Adult Refsum Disease. For patients, this means they may experience a progressive loss of vision (retinitis pigmentosa), starting with night blindness and narrowing of the visual field. They may also develop numbness and weakness in their hands and feet, balance problems, hearing loss, and loss of the sense of smell. Refsum disease is inherited in an autosomal recessive pattern. This means that a person must inherit two mutated copies of the PHYH gene—one from each parent—to develop the condition. The parents, who each carry one mutated copy, are called carriers; they typically do not show any symptoms because their one working copy produces enough of the enzyme. For families, understanding this inheritance pattern is important for genetic counseling, as siblings of an affected person have a 25% chance of also having the disease. While there is no cure, the condition can be managed by strictly limiting foods that contain phytanic acid, which helps prevent the toxic buildup and slows the progression of symptoms.

Gene description: Encodes phytanoyl-CoA hydroxylase, an enzyme involved in the alpha-oxidation of branched-chain fatty acids.

Patient and family guide: The PHYH gene provides the instructions for making an important enzyme called phytanoyl-CoA hydroxylase. This enzyme acts like a specialized recycling worker inside our cells, specifically in compartments called peroxisomes. Its main job is to break down a specific type of fat called phytanic acid. Phytanic acid is not made by our bodies; we only get it from the foods we eat, particularly dairy products, beef, lamb, and certain types of fish. When the PHYH gene has a mutation, the enzyme it produces doesn't work properly or is missing entirely. As a result, the body cannot break down phytanic acid, causing it to build up to toxic levels in the blood and tissues. This buildup is particularly harmful to the nervous system and the eyes, leading to a condition known as Adult Refsum Disease. For patients, this means they may experience a progressive loss of vision (retinitis pigmentosa), starting with night blindness and narrowing of the visual field. They may also develop numbness and weakness in their hands and feet, balance problems, hearing loss, and loss of the sense of smell. Refsum disease is inherited in an autosomal recessive pattern. This means that a person must inherit two mutated copies of the PHYH gene—one from each parent—to develop the condition. The parents, who each carry one mutated copy, are called carriers; they typically do not show any symptoms because their one working copy produces enough of the enzyme. For families, understanding this inheritance pattern is important for genetic counseling, as siblings of an affected person have a 25% chance of also having the disease. While there is no cure, the condition can be managed by strictly limiting foods that contain phytanic acid, which helps prevent the toxic buildup and slows the progression of symptoms.

Gene function: PHYH catalyzes the first step in the alpha-oxidation pathway of branched-chain fatty acids, specifically phytanic acid. This pathway is crucial for the degradation of phytanic acid, which is obtained from the diet. In the retina, proper lipid metabolism is essential for photoreceptor membrane integrity and function. Accumulation of phytanic acid due to PHYH deficiency is toxic to retinal cells, leading to degeneration.

Protein structure: The PHYH gene encodes the protein phytanoyl-CoA hydroxylase (PhyH), which is a 338-amino acid enzyme with a molecular weight of approximately 41.2 kDa. The protein is synthesized with a cleavable peroxisomal targeting signal type 2 (PTS2) at its N-terminus, which is required for its import into the peroxisome via the PEX7 receptor. Once inside the peroxisome, the targeting signal is cleaved to produce the mature, active enzyme. Structurally, PhyH belongs to the 2-oxoglutarate-dependent oxygenase superfamily. X-ray crystallography has revealed that the core of the human PhyH protein consists of a double-stranded beta-helix fold, which is characteristic of this enzyme family. The active site contains a highly conserved iron-binding motif formed by three specific amino acid residues (His175, Asp177, and His264) that coordinate the essential Fe2+ cofactor. The structure also includes a distinct binding pocket for the cosubstrate 2-oxoglutarate. Proper folding and assembly of these domains are critical for the enzyme's catalytic activity, and many pathogenic mutations cluster around these active site regions, disrupting the binding of iron or 2-oxoglutarate.

Molecular function: The PHYH gene encodes the enzyme phytanoyl-CoA hydroxylase (PhyH), which is a peroxisomal protein essential for the alpha-oxidation of branched-chain fatty acids. Specifically, PhyH catalyzes the first step in the degradation of phytanic acid (3,7,11,15-tetramethylhexadecanoic acid), a 20-carbon branched-chain fatty acid derived exclusively from the diet. Because the presence of a methyl group at the 3-position (beta-carbon) of phytanic acid blocks standard beta-oxidation, it must first undergo alpha-oxidation to remove the terminal carboxyl group. In this pathway, phytanic acid is first activated to phytanoyl-CoA. PhyH, acting as a dioxygenase, then hydroxylates phytanoyl-CoA at the alpha-carbon to form 2-hydroxyphytanoyl-CoA. This reaction requires iron (Fe2+) as a cofactor and 2-oxoglutarate as a cosubstrate, with the latter being decarboxylated to succinate and carbon dioxide in the process. The 2-hydroxyphytanoyl-CoA is subsequently cleaved to form pristanal, which is oxidized to pristanic acid. Pristanic acid can then undergo standard beta-oxidation in the peroxisome. When PHYH is mutated and deficient, this critical alpha-oxidation step is blocked, leading to the systemic accumulation of phytanic acid in blood and tissues. In the retina, the accumulation of phytanic acid is toxic to the retinal pigment epithelium (RPE) and photoreceptors. It incorporates into cell membranes, disrupting their structure and function, and interferes with cellular signaling and metabolism, ultimately leading to the progressive cell death characteristic of retinitis pigmentosa and the other neurological manifestations of Refsum disease.

Expression pattern: The PHYH gene is expressed in various tissues throughout the body, reflecting its role in the ubiquitous process of fatty acid metabolism. High levels of expression are found in the liver and kidney, which are primary sites for the alpha-oxidation of branched-chain fatty acids like phytanic acid. It is also expressed in T-cells. In the context of the eye, PHYH is expressed in the retinal pigment epithelium (RPE) and the neurosensory retina. Within the retina, the proper function of the RPE is critical for the maintenance and survival of photoreceptor cells. The RPE is involved in the phagocytosis of shed photoreceptor outer segments and the recycling of visual cycle molecules. While PHYH is not exclusively specific to the eye, its deficiency leads to the accumulation of phytanic acid, which is particularly toxic to retinal cells, leading to the progressive degeneration of photoreceptors and the RPE, manifesting clinically as retinitis pigmentosa.

Mutation spectrum: The mutation spectrum of the PHYH gene includes a variety of pathogenic variants that lead to a loss of phytanoyl-CoA hydroxylase function. Over 100 different mutations have been identified, encompassing missense, nonsense, frameshift (due to small insertions or deletions), and splice-site mutations. Large genomic deletions are less common but have been reported. These mutations are distributed throughout the gene, affecting various functional domains of the protein, including the iron-binding and 2-oxoglutarate-binding sites. While many mutations are private to specific families, some variants are more frequently observed in certain populations. For example, the splice-site mutation c.135-2A>G (which leads to the skipping of exon 3) and the missense mutation p.Arg275Trp are among the more commonly reported pathogenic variants in individuals of European descent. The mutations generally result in a severely truncated, unstable, or enzymatically inactive protein, completely disrupting the alpha-oxidation of phytanic acid.

Pathogenic variants: 1. c.135-2A>G (Splice acceptor variant): This is one of the most common mutations, altering the splice acceptor site of intron 2. It leads to the skipping of exon 3 (an in-frame deletion of 111 base pairs, p.Tyr46_Arg82del), resulting in an enzymatically inactive protein and classic Refsum disease. 2. p.Arg275Trp (c.823C>T): A frequently reported missense mutation that substitutes tryptophan for arginine at position 275. This residue is critical for binding the cosubstrate 2-oxoglutarate, and the mutation abolishes enzymatic activity. 3. p.Asn269His (c.805A>C): A missense mutation that affects a conserved residue near the active site. It causes partial uncoupling of 2-oxoglutarate conversion from phytanoyl-CoA oxidation, leading to loss of function. 4. p.Gln176Lys (c.526C>A): This missense mutation occurs near the iron-binding site of the enzyme. It disrupts the proper coordination required for the dioxygenase activity, resulting in a non-functional protein. 5. c.164delT (p.Leu55Argfs*12): A single base pair deletion that causes a frameshift and introduces a premature stop codon shortly after, leading to a severely truncated and non-functional protein.

Clinical significance: Mutations in the PHYH gene are the primary cause of Adult Refsum Disease (ARD), an autosomal recessive metabolic disorder characterized by the accumulation of phytanic acid. The clinical manifestations of ARD are multisystemic, with retinitis pigmentosa (RP) being the most consistent and often the earliest presenting feature. Patients typically experience night blindness in childhood or adolescence, which progresses to visual field constriction and decreased central visual acuity. Other classic signs include anosmia (loss of smell), which is present in the vast majority of patients, and a mixed motor and sensory polyneuropathy that is chronic, progressive, and can lead to severe muscular weakness and atrophy in the distal limbs. Additional clinical features include sensorineural hearing loss, cerebellar ataxia leading to unsteadiness of gait, and skeletal abnormalities such as shortened metacarpals and metatarsals. Some patients also develop ichthyosis (dry, scaling skin). A particularly severe and potentially life-threatening manifestation is cardiac involvement, which can present as arrhythmias and cardiomyopathy, and is a frequent cause of death in ARD. The onset of symptoms is highly variable, ranging from early childhood to over 50 years of age, and the disease course can be characterized by periods of acute exacerbation triggered by stress, weight loss, or infection, interspersed with chronic progression.

Inheritance: Autosomal Recessive

Chromosomal location: 10p13

Genotype-phenotype correlations: In PHYH-related Adult Refsum Disease, there are generally no strict genotype-phenotype correlations that have been robustly established. The disease is characterized by significant clinical variability, even among individuals with the same pathogenic variants or within the same family. The age of onset, the severity of symptoms, and the specific combination of clinical features (such as the presence or absence of ichthyosis or skeletal abnormalities) can vary widely. This variability suggests that other factors, particularly environmental and dietary influences, play a major role in determining the disease phenotype. Because phytanic acid is derived entirely from dietary sources (such as dairy products, ruminant meats, and certain fish), the amount of phytanic acid consumed and the individual's overall metabolic state (e.g., periods of weight loss or stress that mobilize fat stores) strongly influence the accumulation of the toxic metabolite and the subsequent severity and progression of the disease. Therefore, the clinical course is more closely related to dietary management and plasma phytanic acid levels than to the specific underlying PHYH mutation.

Research and therapeutic approaches: The primary and most effective therapeutic approach for PHYH-related Refsum disease is dietary modification. Because phytanic acid is derived entirely from exogenous sources, a strict diet low in phytanic acid and its precursor, phytol, is the cornerstone of management. Patients must avoid ruminant meats (beef, lamb), dairy products, and certain types of fish. When adhered to strictly, this diet can significantly lower plasma phytanic acid levels, halt the progression of neuropathy and ataxia, and improve ichthyosis, although it generally does not reverse the visual or hearing loss that has already occurred. In acute presentations or when dietary management is insufficient to lower extremely high phytanic acid levels rapidly, plasmapheresis (plasma exchange) or lipid apheresis is utilized. This procedure physically removes the phytanic acid-laden lipoproteins from the blood, providing rapid clinical improvement, particularly in cases of severe neuropathy or cardiac arrhythmias. Supportive therapies are also crucial, including hearing aids or cochlear implants for deafness, physical therapy for neuropathy, and standard ophthalmologic care for retinitis pigmentosa, such as cataract surgery if needed. Currently, there are no approved gene therapies or targeted pharmacological treatments (like small molecules or antisense oligonucleotides) specifically for PHYH mutations. While gene therapy has seen success in other inherited retinal diseases (e.g., Luxturna for RPE65), Refsum disease presents a unique challenge because it is a systemic metabolic disorder, not just an isolated retinal dystrophy. Effective gene therapy would likely need to target the liver, the primary site of phytanic acid metabolism, rather than just the eye. Research in animal models continues to explore ways to upregulate alternative metabolic pathways or deliver functional PHYH genes, but these approaches have not yet reached clinical trials.

Diagnostic testing: Diagnosis of PHYH-related Refsum disease typically begins with clinical suspicion based on the classic tetrad of retinitis pigmentosa, peripheral neuropathy, cerebellar ataxia, and elevated protein in the cerebrospinal fluid, along with anosmia and hearing loss. The biochemical hallmark and primary screening test is the measurement of plasma phytanic acid levels, which are significantly elevated in affected individuals. However, because elevated phytanic acid can also occur in other peroxisomal disorders, confirmatory testing is essential. Molecular genetic testing is the definitive method for diagnosing PHYH mutations. This is often performed using targeted gene panels for inherited retinal diseases, ataxia, or peroxisomal disorders, which include the PHYH gene alongside PEX7 (the other gene associated with Refsum disease). Whole exome or whole genome sequencing may also be utilized, particularly when the clinical presentation is atypical. If genetic testing is inconclusive, enzymatic assays measuring phytanoyl-CoA hydroxylase activity in cultured skin fibroblasts can confirm the functional deficiency. Genetic counseling is crucial for affected families, as the condition is inherited in an autosomal recessive manner, meaning parents of an affected individual are obligate carriers and siblings have a 25% chance of inheriting the disease. Carrier testing for at-risk relatives and prenatal diagnosis are possible once the pathogenic variants in the family have been identified.

Animal models: A key animal model used to study PHYH function and Refsum disease pathogenesis is the Phyh knockout mouse (Phyh-/-). When fed a standard rodent diet, these mice do not display obvious abnormalities because their diet is naturally low in phytol and phytanic acid. However, when challenged with a phytol-enriched diet, they accumulate high levels of phytanic acid in tissues, closely mimicking the biochemical hallmark of human Refsum disease. Studies in these phytol-fed Phyh-/- mice have revealed significant pathological effects, including severe weight loss, hepatic steatosis, and peripheral neuropathy. Notably, the mice develop ataxia accompanied by a specific loss of Purkinje cells in the cerebellum, providing critical insights into the mechanisms underlying the cerebellar ataxia seen in patients. This model has been instrumental in demonstrating that phytanic acid accumulation is directly toxic to the nervous system and in testing potential therapeutic interventions, such as the use of peroxisome proliferators like fenofibrate to lower phytanic acid levels.

Population genetics: Adult Refsum Disease caused by PHYH mutations is a very rare disorder, with an estimated overall prevalence of approximately 1 in 1,000,000 individuals. Because it is so rare, the general population carrier frequency is very low. However, the disease has been reported worldwide across various ethnic groups. While there is no single predominant founder mutation globally, certain variants may be more concentrated in specific populations due to historical isolation or consanguinity. For instance, the c.135-2A>G splice-site mutation and the p.Arg275Trp missense mutation are more frequently observed in patients of European ancestry. In populations with higher rates of consanguineous marriages, the incidence of this autosomal recessive condition may be relatively higher, and affected individuals are more likely to be homozygous for rare, private mutations.

Selected references: 1. Jansen GA, et al. Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene. Nat Genet, 1997. PMID: 9326947 2. Mihalik SJ, et al. Identification of PAHX, a Refsum disease gene. Nat Genet, 1997. PMID: 9326946 3. Jansen GA, et al. Human phytanoyl-CoA hydroxylase: resolution of the gene structure and the molecular basis of Refsum's disease. Hum Mol Genet, 2000. PMID: 10767344 4. Waterham HR, et al. Adult Refsum Disease. GeneReviews, 2021. PMID: 20301526 5. Ferdinandusse S, et al. Ataxia with loss of Purkinje cells in a mouse model for Refsum disease. Proc Natl Acad Sci U S A, 2008. PMID: 19004801 6. McDonough MA, et al. Clinical mutations in Refsum disease: structural and functional investigations of phytanoyl-CoA 2-hydroxylase. J Biol Chem, 2005. PMID: 16105837 7. Wierzbicki AS, et al. Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation. J Neurochem, 2002. PMID: 11948235